Engineering complex biologics for the two hardest neighborhoods in medicine: the failing heart and the solid tumor.
Above: the company mark, photographed in the only light a 40-person biotech can afford - the glow of a clinical readout at 6 a.m.
In a building off West Watkins Mill Road in Gaithersburg, a team of about forty people is running three clinical trials at once. One asks whether a failing heart can be coaxed into rebuilding itself. The other two ask whether a tumor can be talked into giving itself up.
This is Salubris Biotherapeutics. It does not make pills that slow a decline. It is chasing biologics - engineered proteins and antibodies - aimed at changing the trajectory of the disease itself. That is a harder thing to do, which is rather the point. Easy targets already have crowds standing on them.
There is a growth factor called neuregulin-1, NRG-1, that the body uses to keep heart muscle healthy. Give it to a failing heart and good things start to happen. Give it for long and bad things start to happen too. For years that trade-off kept a genuinely promising idea parked in the lab.
The reason turned out to be wiring. NRG-1 talks to two different receptors. One of them, ErbB4, appears responsible for the regenerative effects in the heart. The other, ErbB3, appears responsible for the side effects nobody wants. Plain NRG-1 hits both. So the helpful signal always arrived with the unwelcome one attached.
Cancer posed a different version of the same puzzle: how do you point a toxic payload at a tumor without poisoning everything else? The answer there is finding an address that exists on cancer cells and almost nowhere else.
Salubris Biotherapeutics was founded in 2016 by John Li, a drug-discovery veteran with over fifteen years across cancer, cardiovascular, respiratory and autoimmune biology, who served as its founding president and CEO. Sam Murphy - a Penn-trained cell and molecular biologist who later took the chief-executive seat - co-built the company after conversations with the leadership of China's Shenzhen Salubris Pharmaceuticals.
The structure is the tell. SalubrisBio was set up as the US science arm of Shenzhen Salubris, and it has run largely on its parent's money rather than the usual venture syndicate. No board of a dozen investors to please. One backer, one mandate: build first-in-class biologics in cardiology and oncology, the areas most teams avoid precisely because they are so hard.
Every program here runs on the same instinct - turn on the signal you want, leave the one you don't. JK07 does it with an antibody-fusion design that blocks ErbB3 while delivering the NRG-1 fragment to ErbB4. JK06 does it by finding a target that healthy adults barely express. The thread is selectivity, all the way down.
An antibody-fusion protein pairing a human IgG1 antibody with an NRG-1 fragment. It blocks the troublesome ErbB3 pathway and selectively stimulates regenerative ErbB4 - aiming to restore, not just slow, cardiac function. In the RENEU-HF Phase 2 study.
An IL-15 / CTLA-4 antibody-fusion that wakes up natural-killer cells inside the tumor and reverses immunosuppression. Being explored alongside the PD-1 inhibitor pembrolizumab.
A first-in-class biparatopic antibody-drug conjugate targeting 5T4, an oncofetal protein found across many solid tumors but rare in healthy tissue. Picomolar affinity, enhanced internalization, MMAE payload.
Skepticism is the correct posture for any clinical-stage biotech - most molecules fail, and honest people say so. What Salubris can point to is movement: trials that opened, patients who enrolled, and early signals worth presenting at the field's biggest meetings.
Partnerships round out the picture: the JK08 oncology program is being studied in combination with pembrolizumab, the widely used PD-1 inhibitor - a sign that Salubris is willing to plug its biology into the established standard of care rather than insist on going it alone.
"Salubris" is Latin for healthful. The company states its purpose plainly: to develop transformative therapeutic molecules that deliver clinically meaningful improvements in disease burden and quality of life for patients with significant unmet medical needs.
Developing innovative and transformative therapeutic molecules to provide clinically meaningful improvements in disease burden and quality of life for patients with significant unmet medical needs.
- Salubris Biotherapeutics, company missionHeart failure is a disease of slow loss, and most therapies are built to slow that loss a little more. A drug that helps the heart rebuild - if JK07 proves out across the full RENEU-HF readout - would be a different category of thing. The same logic holds for a clean-targeting ADC in tumors that currently have few options.
None of this is guaranteed. Phase 2 is where promising ideas often go to disappoint. But that is exactly the wager Salubris signed up for in 2016: pick the hard problems, engineer for selectivity, and let the data decide.
The team is still about forty people. The parent still writes the checks. And the question on the screen is the same one it has always been - can you turn on the good signal and leave the bad one off? They have spent a decade building three different answers. Soon the trials will say whether they were right.